low - Clinical diagnostics for cancer patients are non-discretionary medical services with minimal GDP sensitivity; oncologists order MRD tests based on clinical guidelines rather than economic conditions. However, pharma R&D budgets (affecting collaboration revenue) exhibit moderate cyclical sensitivity during severe recessions when biotech funding contracts. The 54% revenue growth rate reflects commercial launch dynamics rather than economic cycle positioning.

Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for pre-profitable biotech stocks (ADPT trades at 8.6x sales, sensitive to risk-free rate changes); (2) Tighter financial conditions reduce biotech sector funding availability, potentially impacting future partnership economics and capital raising ability. However, the company's $400M+ cash position (implied by 3.34x current ratio) and declining cash burn provide 3-4 year runway, reducing near-term financing pressure. Rate impacts are primarily valuation-driven rather than operational.

growth - The stock attracts growth investors focused on commercial-stage biotech with platform technology potential, evidenced by 89% one-year return and 8.6x sales valuation. Investors are underwriting rapid revenue scaling (55% YoY growth), pathway to profitability within 2-3 years, and optionality from pharma partnerships generating milestone/royalty streams. The negative cash flow and high P/S multiple indicate this is not a value or income play; momentum investors have driven recent outperformance as MRD testing adoption accelerates. Institutional biotech specialists and healthcare-focused growth funds represent core holder base.